Q-omics provides the consensus-scored KRT18P16 profile across patient tissues and cancer cell-line models. KRT18P16 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT18P16 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, KRT18P16 RNA expression shows 9,950 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where KRT18P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P16 survival associations across molecular data types. KRT18P16 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P16 RNA expression–survival associations across cancer types. High KRT18P16 expression shows unfavorable associations in LUAD, CHOL, PAAD, LAML and ACC, but favorable associations in THCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT18P16 RNA expression.
This table summarizes KRT18P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P16 shows higher tumor expression in COAD, LUAD, STAD, BRCA, KIRC and BLCA. The COAD box plot shows higher KRT18P16 RNA expression in tumor versus normal tissue (log2 FC = +0.394, t-test p < 0.001).
This table shows molecular features associated with KRT18P16 in patient tissues and cancer cell lines. In patient samples, KRT18P16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
